HORMAD1

Across TCGA pan-cancer cohorts, HORMAD1 Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated HORMAD1 data layer compared with 25 for mass-spec protein.

The strongest signal is observed in kidney chromophobe (KICH), where higher HORMAD1 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated HORMAD1 expression acts as an unfavorable survival marker.

KICH, SARC, and TGCT are the cancer types where HORMAD1 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
KICH	DFS	Median	All	0.102	0.848	.004	13	view →
SARC	DFS	Median	All	0.024	0.611	<.001	6	view →
TGCT	DFS	Median	All	0.051	0.674	<.001	6	view →
STAD	OS	Median	All	0.193	0.583	.034	6	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
CHOL	OS	Median	All	0.155	0.725	.029	3	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

HORMAD1–KICH (DFS)

Open the KICH breakdown →